Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and ...

Cipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the ...

Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not recommended for ...

Cipla received approval from India's Central Drugs Standard Control Organisation to distribute and market Afrezza inhalation ...

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...